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Abstract 
Graphene is an innovative nanomaterial, made of two-dimensional honeycomb-like carbon lattice, 
with potential in many different applications. Studying the behaviour of graphene-related materials 
(GRMs) in biological systems is, therefore, crucial to assess possible side effects. In this work is 
studied the biotransformation and biological impact of few layer pristine graphene (FLG) and 
graphene oxide (GOX), following ingestion as exposure route. To mimic FLG and GOX ingestion, an 
in vitro digestion assay based on a standardized operating procedure (SOP) is applied. The assay 
simulates the human ingestion of GRMs during their dynamic passage through the different 
environments of gastro-intestinal (GI) tract (salivary, gastric, intestinal). Physical-chemical changes 
of GRMs during the digestion process are assessed through a detailed Raman spectroscopy 
characterization. Moreover, the effect of chronic exposure to digested GRMs on integrity and 
functionality of an in vitro model of intestinal barrier is also determined according to a second SOP. 
Our results showed that theFLG and GOX nanoflakes aggregates after experiencing the passage 
through the different environments of GI tract, with evident doping effects, due to the interaction of 
GRMs with digestive juice components and the strong pH variations. Interestingly, neither structural 
changes nor degradation of the nanomaterials are observed, suggesting that GRMs are biopersistent 
nanomaterials when administered by oral route. Chronic exposure to digested GRMs does not affect 
intestinal barrier integrity and is not associated to inflammation and cytotoxicity, though possible 
long-term adverse effects cannot be ruled out, due to the observed biodurability of the materials. 
Limited cellular internalization of digested GRMs is detected in the epithelial barrier, likely due to 
the formation of large GRM aggregates, with a prevalent localization in endo-lysosomes. These 
findings have important implications in the hazard identifications of GRMs upon ingestion, and pave 
the way to address their possible bio-applications. 
 
Keywords: graphene, graphene oxide, digestive juices, biotransformation, intestinal barrier, 
inflammation, cytotoxicity 
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Introduction 
In the latest years, the interest in graphene have grown continuously  1-2. Graphene is a single 
layer of sp2-hybridized carbon atoms tightly packed in a two-dimensional honeycomb lattice1-
2(PNAS, Novoselov 2005). The group of graphene-related materials (GRMs) comprises single-layer 
graphene, few-layer graphene (FLG), graphene oxide (GOX), reduced graphene oxide (rGOX), 
graphene nanosheets, graphene nanoribbons, and graphene quantum dots 2-4. GRMs have distinctive 
characteristics e.g.  that make them interesting candidates for technological and biomedical 
applications, ranging from (opto)electronic to electrochemical devices, energy storage, cell imaging, 
drug delivery, and biosensors 3, 5-8. Moreover, the use of graphene as nanofiller in food packaging has 
also been investigated because of its exceptional ability to limit oxygen permeation (some comparison 
with an state-of the-art material could aid to strength this idea) and light transmission in polymeric 
films (why is this important, also is necessary to put a number and/or comparison with a current used 
material) 9-11. 
The integration of GRMs into consumer products makes crucial to assess their potential risk for 
humans, by defining their toxicological profiles and biological fate within the exposed organisms 12. 
Exposure to GRMs can mainly occur via inhalation, ingestion, and/or skin contact. Amongst these, 
inhalation is considered as the most relevant way of entrance of GRMs in the human body and, hence, 
several in vitro and in vivo studies have recently focused their attention on this route of exposure 3, 13-
14. After inhalation, however, GRMs may also enter the digestive apparatus, through swallowing 15-
17. In addition, unintentional direct ingestion of GRMs could occur from contaminated waters or upon 
their release from food packaging. Despite such important route of entrance, few works on the fate 
and toxicological effects of GRMs upon oral exposure have been reported to date 18-21. Moreover, in 
vitro models only partially mimic the real in vivo environment, e.g., GRMs directly suspended in cell 
culture media without previous contact with GI juices 18 or pre-incubated with acidic buffers that only 
account for the low pH of the gastric compartment 19. Therefore, in vitro data are poorly comparable 
to complex in vivo conditions, including strong pH shifts and variable concentrations of salts and 
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enzymes during ingestion. Hence, a more reliable approach considering all steps occurring after oral 
ingestion is required for a realistic assessment of biotransformation of GRMs in the GI tract. In fact, 
as for other nanomaterials22-25, the unique physical-chemical characteristics of GRMs may change 
depending on the surrounding conditions, such as temperature, pH, concentration, salts, etc, that, in 
turn, may modify the toxicological profile of GRMs on biological systems. Moreover, recent findings 
have shown that carbon nanomaterials, including GOX and oxidized carbon nanotubes (CNTs), may 
be degraded by oxidase enzymes, such as horseradish peroxidase (HRP) and human myeloperoxidase 
(hMPO) both in vitro and in vivo 26-28. Notably, as also proposed in some recent categorization 
schemes for nanomaterials 29-30, a major concern for the potential harmfulness of GRMs is related to 
their biological transformation/persistence or release of toxic compounds through degradation.  
Different digestion models have been applied to test changes in nanoparticle behaviour, mainly 
focusing on aggregation/agglomeration and cytotoxicity 31 24, 32 33. In this work, we used a dynamic 
in vitro digestion assay, developed to mimic the human ingestion of nanoparticles and monitor their 
biotrasformations during the passage through the GI tract simulated environments (salivary, gastric, 
intestinal) 24. The assay is part of a SOP 34 developed in the EU project NANoREG (A common 
European approach to the regulatory testing of nanomaterials. http://www.nanoreg.eu/). The 
application of SOPs has the scope to foster data reproducibility by lowering result variability, which 
often affects the benchmarking analysis among nanomaterials 35. The assay had been validated using 
a range of reference nanoparticles (from JRC European repository list) for which a detailed physical-
chemical characterization in pristine conditions is available (https://ec.europa.eu/jrc/en/scientific-
tool/jrc-nanomaterials-repository). Here, we investigated biotransformation, biodurability in GI 
fluids, cell uptake, cytotoxicity, and inflammatory response of FLG and GOX upon the in vitro 
digestion. In particular, the first objective of this study is the understanding of the impact of each step 
of the in vitro digestion process on the physical-chemical properties of FLG and GOX flakes by 
Raman spectroscopy. The second objective is a thorough cytotoxicological investigation of digested 
GRMs on an in vitro model of intestinal barrier, a widely adopted test system by pharmacological 
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industries and regulatory authorities 36. A second NANoREG SOP method was used also for this 
analysis (De Angelis et al. “Standard Operating Procedure for evaluation of NPs impact on Caco2 
cell barrier model” https://circabc.europa.eu/sd/a/fe1ea854-be73-4f58-a2ba-
4bc2ce42ee62/SOP%20for%20the%20evaluation%20of%20NMs%20impact%20on%20Caco2%20
cell%20barrier%20model%2029052015%20V9.pdf).  
 
Materials and Methods 
GRM synthesis and characterization 
Few layer pristine graphene (FLG) is prepared by ball-milling as described elsewhere 37. 
Monolayer/few layer graphene oxide (GOX) is provided by Grupo Antolin Ingeniería (Burgos, Spain). 
GRM morphology and lateral size are analyzed by Jeol JEM 1011 transmission electron microscope 
(TEM) (Jeol, Japan). Thermogravimetric analysis (TGA) is carried out using a TGA Q50 (TA 
Instruments) at 10 °C min-1 under nitrogen flow, from 100 °C to 800 °C. Measurements of zeta 
potential of FLG and GOX are carried out with a Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK) at 25 °C in low ionic strength buffers at different pH. All measurements ae 
performed in triplicate for each sample.  
 
In vitro digestion assay 
The digestion of GRMs is carried out by an in vitro digestion assay that simulates the human ingestion 
of nanomaterials. The assay is based on a dynamic model developed by Bove et al.24 that is also 
available as a SOP 34 from the European project Nanoreg (NANoREG – A common European 
approach to the regulatory testing of nanomaterials. http://www.nanoreg.eu/). Briefly, the assay 
employs artificial juices simulating the human digestive compartments (mouth, stomach and small 
intestine), which are dynamically added into the Eppendorf tube under stirring conditions. The assay 
is slightly modified. The digestive juices are prepared in sterile conditions by combining salt 
solutions, organic compounds and proteins to obtain the final concentrations in a total reaction volume 
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of 10 ml as reported in Table S1. The final pH of each single juice is 6.8 ± 0.1 for saliva, 1.3 ± 0.1 
for stomach, 8.1 ± 0.1 for duodenal and 8.2 ± 0.1 for bile. The juices are pre-heated to 37 °C for at 
least two hours before starting the experiments. All chemicals were purchased by Sigma Aldrich. 
The assay is conducted following the reported procedure: 20 µl of the FLG and GOX dispersions (0.09 
and 0.45 mg ml-1, respectively) are added into a 1.5 mL Eppendorf tube. Afterward, the digestive 
juices are added in a temporal sequence that simulated the transit of food bolus along the 
gastrointestinal apparatus 38. To reproduce the mouth compartment, 60 µl of salivary juice at pH 6.8 
are mixed with 20 µl of the GRM dispersion and shacked at 37 °C for 5 minutes. After incubation, 1 
µl of the mouth sample was collected and dried on a silicon wafer for Raman spectroscopy analysis 
(described below). The remaining sample is used to continue the transit into the stomach. To this aim, 
120 µl of gastric juice are added to the mouth samples, the pH is adjusted to 2.5 ± 0.5 with 1 M NaOH 
and the samples are incubated for further 120 minutes at 37 °C under shaking. At the end of gastric 
digestion, 1 µl of the stomach samples is processed for the Raman analysis. The remaining samples 
are employed to simulate digestion in the small intestine, adding to it 120 µl of duodenal fluid, 60 µl 
of bile salts and 20 µl of 84.7 g l−1 sodium bicarbonate solution and adjusting the pH at 6.5 ± 0.5 with 
3.7% HCl. The shaking is stopped after further 120 minutes of incubation and 1 µl of the samples 
was dried on a silicon wafer for Raman characterization. For biological experiments with Caco-2 cell 
layers, the digestion process is carried out in sterile conditions and the digested GRMs are diluted 1:5 
in cell culture medium before incubation with the epithelia. 
 
Raman spectroscopy 
1 µL of dispersion for each sample was drop cast on a Si wafer (LDB Technologies Ltd.) coated with 
300 nm of thermally grown SiO2. The Raman spectra are measured using a Renishaw confocal 
microscope (514.5 nm laser excitation wavelength with an incident power of ~1 mW on the sample), 
with a 50× objective and a grating of 2400 l/mm. The deposited samples are mapped in rectangular 
areas of ~100 µm × 100 µm. The offset between points in the mapping is set to 5 µm. For statistical 
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analysis, 50 spectra of GRM are selected on each mapping-sample. The FLG and GOX peaks were 
fitted with Lorentzian functions, all the spectra are normalized to the integral intensity of the G band. 
 
Intestinal layer formation and chronic treatment with digested GRMs 
Human colon epithelial (Caco-2) cells (gently provided by Dr. Isabella De Angelis, Istituto Superiore 
di Sanità (ISS), Rome, Italy) are cultured in Dulbecco’s Modified Eagles Medium (DMEM, Sigma-
Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS, Sigma-Aldrich), 1% non-essential 
aminoacids (Invitrogen), 100 U ml-1 penicillin and 100 mgml-1 streptomycin (Sigma-Aldrich). Cells 
were maintained in incubator at 37 °C under a humidified controlled atmosphere and 5% CO2. To 
obtain intestinal epithelia, cells are seeded in 12-well plates onto porous Millicell hanging cell culture 
inserts (Merck Millipore) (d, 12mm; A, 1.1cm2; pore size 0.1 µm) made of polyethylene terephtalate 
(PET) in 0.5 mL of medium at a seeding density of 1.7 x 105 cells/insert in the apical side. 1.5 mL of 
medium are poured in the basolateral compartment. Cells are grown for three weeks, and culture 
medium is changed every two days, to allow the formation of tight junctions and microvilli according 
to the NANoREG SOP “Standard Operating Procedure for evaluation of NPs impact on Caco2 cell 
barrier model”. Before starting each experiment, Trans-Epithelial Electrical Resistance (TEER) is 
measured to verify the correct formation of confluent intestinal layers. The cell inserts are then 
incubated with digested FLG and GOX diluted 1:5 in cell culture medium at the final concentrations 
of 1 and 5 µg ml-1, respectively, for 2 hours every 2 days up to 9 days in order to mimic a chronic 
intestinal exposure. As a control, some cell inserts are incubated with digestive juices without GRMs 
at the same conditions used for digested materials to verify their possible effect on cell layer integrity 
and functionality. 
 
Trans-Epithelial Electrical Resistance (TEER) measurements 
Before and after 1, 5 and 9 days of incubation with digested GRMs, integrity of differentiated Caco-
2 cell epithelia are evaluated by TransEpithelial Electrical Resistance (TEER) using a chop-stick 
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electrodes device (Millicell-ERS voltmeter, Millipore). TEER values are expressed as Ohms (Ω) x 
cm2 and are calculated according to the following equation(REFERENCE): 
TEER = [Ω cell monolayer - Ω filter (cell-free)] x filter area (1.12 cm2) 
Inserts are considered suitable for experiments if TEER value is >150 Ω x cm2.  
 
Lucifer yellow (LY) assay 
At the end of experiments, the impact of digested GRMs on epithelium integrity is evaluated by 
lucifer yellow (LY, Sigma) assay to determine any difference in this paracellular marker ability to 
cross the monolayer between GRM-treated inserts and untreated inserts. After 1, 5 and 9 days of 
incubation with digested GRMs, apical (Ap) and basolateral (Bl) media are collected and cell layers 
are washed twice with HBSS. Ap compartment was filled with 0.5 ml of 0.4 mg ml-1 LY solution in 
HBSS and Bl compartment with 1.5 ml HBSS. Cells are then incubated for 2 h at 37 °C. After 
incubation, 100 µl of the Bl HBSS of each insert (including free cell inserts) are collected and added 
into a black 96-well plate. LY content is measured by fluorometric detection (ex. 428 nm, em. 536 
nm). The percentage of LY passage in Bl side after treatment is compared to the percentage of LY 
passage in the negative control. 
 
Indirect immunofluorescence and confocal microscopy 
After chronic incubation with digested GRMs, cell layers are fixed with 4% paraformaldehyde for 20 
min at room temperature, permeabilized with 0.01% Triton X100 for 5 min and blocked with blocking 
buffer solution (0.5% bovine serum albumin in PBS) for 20 min. Cells are then stained with 0.1 nM 
Alexa FluorTM 594 Phalloidin for 30 min and Hoechst 33342 (Thermo Fisher Scientific) at a 
concentration of 5 µg ml-1 for 5 minutes, to localize actin microfilaments and cell nuclei, respectively 
. Lysosomes are localized by using anti-LAMP1 primary antibodies (Abcam, ab24170) and Alexa546 
anti-rabbit secondary antibodies (Thermo Fisher Scientific). Cells are incubated with primary 
antibodies in blocking buffer solution (1:200) for 1 hour and after several washes with PBS, cells are 
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incubated with the secondary antibodies (1:500) for 45 min. Confocal microscopy images are 
acquired by a confocal microscope (Leica TCS-SP5) with an oil-immersion 63× objective, 405, 488 
and 561 nm excitation laser wavelengths and a resolution 1024 × 1024 pixels. Z-sectioning images 
are acquired with a z-slice thickness of about 0.7 μm.  
 
Transmission electron microscopy (TEM) 
To observe the formation of microvilli and tight junctions as well as the intracellular localization of 
digested GRMs, the Caco-2 barriers are fixed for 2 h in 1.5% glutaraldehyde in 0.1 M Sodium 
Cacodylate buffer (pH 7.4), post fixed in 1% osmium tetroxide in the same buffer and stained 
overnight with 1% uranyl acetate aqueous solution. The barriers are then dehydrated in a graded 
ethanol series, infiltrated with propylene oxide and embedded in epoxy resin (Epon 812, TAAB). 
Semi-thin and thin sections of the embedded cell monolayer are cut with an ultramicrotome (UC6, 
Leica) equipped with a diamond knife (Diatome). Images are collected with a Jeol JEM 1011 (Jeol, 
Japan) electron microscope, operating at an acceleration voltage of 100 kV, and recorded with a 11 
Mp fiber optical charge-coupled device (CCD) camera (Gatan Orius SC-1000). 
 
Cell viability assay 
Cell viability is evaluated by measuring the cell metabolic activity using CellTiter 96® AQueous One 
Solution Cell Proliferation Assay ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt) MTS assay, Promega). Briefly, 5×103 cells suspended in 100 
µl of cell culture medium are seeded in each well of a 96-well plate. Following 3 days of culture, cells 
are treated with 1 µg ml-1 of digested FLG and 5 µg ml-1 of digested GOX diluted 1:5 in cell culture 
medium for 2 h every day, up to 4 days of culture. 0.05 mg ml-1 of benzalkonium chloride (BC, 
Sigma) in cell culture medium was used as a chemical positive control. Cell treatments with non-
digested FLG and GOX at the same concentrations of digested GRMs and with digestive juices alone 
are used as further controls. After at 24, 48 and 96 h of treatment, cell culture medium of each well 
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is replaced with 100 µl of fresh medium supplemented with 20 µl of MTS reagent and incubated for 
two hours at 37 °C. The optical absorbance is measured at 490 nm using a microplate reader (Synergy 
HT, BioTek) and the raw data are normalized to non-treated cells (considered 100%) to calculate cell 
viability percentage. Experiments are performed in triplicate and data are reported as mean ± standard 
deviation. 
 
LDH assay 
After cell interaction with digested GRMs as described above, to assess the impact on cell membrane, 
the lactate dehydrogenase (LDH) leakage assay is performed onto 96-well microplates by using the 
CytoTox-ONE Homogeneous Membrane Integrity Assay reagent (Promega), following the 
manufacturer’s instructions. LDH released in the extracellular environment is measured with a 10 
min coupled enzymatic assay that results in the conversion of resazurin into fluorescent resorufin 
(560 Ex/590 Em) by using a plate reader (Synergy HT, BioTek). As a negative control, the same 
assay onto untreated cells is performed. To determine the maximum LDH release (positive control), 
2 µl of Lysis Solution are added to positive control wells 10 minutes before the assay was performed. 
Results are normalized with respect to positive control (expressed as 100 %). 
 
Cytokine and chemokine release  
Inflammatory cytokine release (panel: IL-8, MCP-1, IL-1β, IL-6, INFγ, TNFα, MIP1β, RANTES) in 
the apical and basolateral media from the Caco-2 cell layers after 1, 5 and 9 days of chronic treatment 
with digested GRMs are assessed with a Bio-Plex 1 MAGPIX TM Multiplex Reader (Bio-Rad) 
according to the manufacturer’s procedure. The cells were stimulated with 100 ng ml-1 
lipopolysaccharide (LPS, from Escherichia coli 0111-B4, Sigma–Aldrich, cat. no. L4391) as positive 
control. 
 
Results and Discussion 
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Biotransformation of GRMs during the digestion process 
A schematic representation of the in vitro digestion assay adapted for GRM ingestion is reported 
in Figure 1 and Table S1. This proposed model mimics the gastro-intestinal passage and simulates 
the oral, gastric, and small intestine conditions. To mimic the gastro intestinal process, synthetic 
digestive juices are used, and the pH changes, transit times, relevant enzymes, and protein 
compositions during the digestion process are taken into account, as described in previous reports 24, 
38. In this study, FLG and GOX flakes are used as model GRMs. FLG flakes are obtained by 
exfoliation of graphite through interaction with melamine by ball-milling treatment 37. After 
exfoliation, melamine is removed by filtration with hot water (write temperature) to obtain stable 
dispersions of FLG. The final FLG concentration as estimated to be 0.09 mg ml-1 with melamine 
traces (0.09 ppm). GOX flakes are obtained through oxidation of carbon fibers (GANF Helical-Ribbon 
Carbon Nanofibers, GANF). To remove the presence of acids, the initial GOX suspensions 
(concentration < 1 mgml-1) are rinsed with MilliQ water by centrifugation, at 4000 rpm (write the 
Centrifuge or rotor model or “g” force) for 30 min, until a pH value of ~5 is reached.  
The aggregation state and the surface charge of nanomaterials  influence their biological 
behaviour. Therefore, the as-prepared GRMs are characterized by transmission electron microscopy 
(TEM), thermogravimetric analysis (TGA), and zeta potential. TEM analysis reveal a broad lateral 
size distribution of both GRMs (Figure 2 c and d), in line with previously reported results 39,the mean 
flake length is similar for both materials  c.a. 400 nm. Representative flakes, with many visible 
wrinkles, of FLG and GOX, are shown in Figure 2 a and b, respectively. Thermogravimetric analysis 
reveals a weight loss of 8% for FLG at 600 oC, indicating a low quantity of oxygen groups generated 
by the exfoliation process, while a weight loss of 46% in the case of GOX at the same temperature 
(Figure 2 e and f). Moreover, zeta potential indicated a negative charge around -20 mV for FLG and 
-35 mV for GOX in MilliQ water (Figure 2 g and h). 
According to their route of entrance in biological systems, e.g. XX,YYY, zZZ,  nanomaterials 
experience different environments that affect their original chemical/physical properties.(REF) For 
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instance, it has been reported that, during digestion, silver nanoparticles are fully dissolved to silver 
ions that, in turn, interact with the components of digestive juices, forming secondary silver-organic 
complexes 24. Moreover, metal containing nanoparticles, once internalized by cells according to 
endocytosis pathways, can be degraded in the lysosomal compartment, due to the low pH and 
degradative environment 22-23, 40. It has also been recently reported that FLG and GOX can be degraded 
by peroxidases (hMPO and HRP) in vitro 26-28. 
Starting from these observations, Raman spectroscopy analysis is carried out on GRMs incubated 
at specific time intervals in the different digestive juices, to assess their 
biotransformation/biodegradation in conditions that mimic the digestion process. Raman 
spectroscopy has demonstrated to be a powerful tool for the characterization of nanomaterials, e.g., 
in terms of doping 41-43, functionalization 44, oxidation 45-46. In particular, for GRMs, Raman 
spectroscopy has been widely used to identify the number of layers, defects type and doping, disorders 
on the crystalline structure, chemical modifications, just to cite a few 47-50. Thus, Raman analysis 
provide important information about the possible chemical and physical changes in the graphene 
flakes as they go through the simulated digestive tract. The Raman spectrum of graphene is composed 
by the G peak, positioned at ∼1580 cm-1, the D peak, positioned at ∼1350 cm-1, and the 2D peak, 
centered at ∼2680 cm-1 in case of a single layer graphene. A detailed physical description of the main 
Raman modes of graphene is reported in the Supporting information. Figure 3 shows representative 
Raman spectra of the FLG, GOX, and the spectra of the different digestive juices: saliva, stomach and 
intestine. We can observe the characteristics D, G, D’ and 2D bands for FLG spectra, as well as the 
typical broad D and G bands, characteristics in GOX. The Raman spectra of the physiological juices 
are characterized by two main bands cantered at 1450 and 2900 cm-1.  
Doping (e.g., electrostatic, metallic contacts, chemical, heteroatoms or optical) strongly affects 
the G, D, and 2D band lineshapes/positions45, 51-53. In particular, the position and full width at half 
maximum (FWHM) of the G band (pos(G) and FWHM(G), respectively), change due to electron-
phonon coupling and the Kohn anomaly at the Γ point42, 50. The frequency of the G band has the 
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lowest value when the Fermi level is at the Dirac point, and the pos(G) stiffens as the doping 
concentration increases43. Contrary, the FWHM(G) decreases as the doping concentration increases51-
52. While the G band obeys to the doping concentration, the 2D band is sensitive to the doping type, 
this means that pos(2D) increases if the doping is p-type and decreases for n-type doping51. The 2D 
band intensity, I(2D), is also affected by the doping concentration, but it is insensitive to the doping 
type, decreasing with the increase of doping43, 45. In the same way, as the 2D band is doping-sensitive, 
the first order D band is doping-sensitive as well54. The I(D)/I(G) reaches the minimum value when 
the Fermi level (which can be tuned according to the amount and type of dopants attached to the 
graphene) approaches the Dirac point. I(D)/I(G) reaches the maximum value when the Fermi energy 
is at half of the excitation energy55, i.e., the Pos(D) up-shifts with p-type doping and down shifts with 
n-type doping55. Moreover, also the FWHM increases with n-type doping and decreases for the p-
type one55. Structural defects, aside from being the responsible for the D band activation49, 56, also 
modify significantly the pos(G) and FWHM(G)46, 57, i.e., for a graphene flake with structural defects 
the FWHM(G) is larger than 24 cm-1 46, 57, and the pos(G) can be shifted up to 5 cm-1 46, 57. 
Additionally, the FWHM of all the graphene Raman peaks, i.e., D, D’, G and 2D, increases with the 
presence of defects, while the intensities of the D and D’ increases and the intensity of the 2D 
decreases in the presence of defects54. 
Combined to the fact that the electronic and optical properties of graphene change due to defects 
and doping, the Raman spectra also change with the number of stacked graphene layers47, 58-59, i.e., 
the 2D band changes in lineshape and position for an increasing number of layers47, 58. These 
variations in the Raman spectra make the data interpretation challenging for a heterogeneous sample, 
as it is the case of the mechano-chemical exfoliated graphene or GOX flakes. As a consequence, an 
extensive statistical analysis is a compulsory step, in order to understand the physical/chemical 
changes of graphene/GOX dispersed in biological media.  
The most significant results of the Raman statistical analysis on FLG and GOX are shown in 
Figures 4 and 5. In Figure 4a, the Pos(G) of the FLG (~1582 cm-1) is maintained in saliva and 
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stomach samples. The Pos(G) in intestine down-shifted to ~1580 cm-1, due to the doping influence 
from the constituents of the digestive juices. The doping hypothesis is corroborated observing the 
FWHM(G) of the samples (Figure 4b), which stiffen from 22 to 18 cm-1, when the FLG passed from 
saliva to stomach/intestine. In the normalized intensity of the D band (I(D)/I(G)) (Figure 4c), the 
maximum population is found at 0.3, which is constant both saliva and intestine. Then, the I(D)/I(G) 
distribution grows in stomach due to the contribution of small flakes that aggregate in the presence 
of low pH, as also demonstrated by Zeta-potential titration measurements (Figure S1, right panel). 
In particular, at highly acidic pH (1.2), Zeta-potential values of FLG are close to 0 mV, thus falling 
in the range of instability of colloidal suspensions 60. The FWHM(D) (Figure 4d) ranged from 32 to 
60 cm-1 for the FLG, indicating that the sample is composed by a broad flake size distribution, since 
FWHM(D) increases inversely with the crystallite size61-62. Notably, the FWHM(D) for the FLG 
dispersed in saliva and intestine have the same distribution as the one of the pristine sample, while in 
stomach juice the distribution decrease at 30 to 50 cm-1, due to the protonation of the FLG places (p-
type doping)45, 51-53. The formation of structural defects, i.e., creation of sp3 hybridized carbon atoms, 
on the FLG is discarded by the fact that the I(D)/I(G) distribution in intestine peaked at 0.4 and 
spanned from 0 to 1.1, which is the same distribution of the starting FLG sample; a similar behaviour 
is observed for the FWHM(D). The 2D sub-components analysis (Figure S2) showed no changes in 
pos(2D1) and pos(2D2). The intensities of the sub-peak 2D1, I(2D1)/I(G) increase from 0.3 to 0.6 when 
the pH value changed from neutral to acidic (stomach), which led us to conclude that the 2D1 intensity 
is affected by the doping. The intensities of the 2D2, I(2D2)/I(G), remained unchanged for all the 
samples, despite the changes in doping.  
The main GOX-Raman peaks are the G and D bands. Statistical analysis of the GOX Raman data 
made possible to observe the Pos(G) (~1580 cm-1) (Figure 5a) and FWHM(G) (Figure 5b) remained 
unchanged for all the samples, except for the FWHM(G) in intestine, in which the distribution became 
narrow, shifting the maximum population distribution from 100 to 70 cm-1. The stiffening of the G 
band is ascribed to the doping contribution (the charge impurities, i.e., dissolved salts and H+)51. 
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Observing the I(D)/I(G) and FWHM(D) for GOX in intestine and stomach (Figure 5c and d, 
respectively), an intensity reduction and stiffening in the band are clear. Here, the aggregation of the 
flakes and the doping, due to the pH changes as well as the adsorption of juice components like 
proteins are the responsible of this behaviour 63 (Figure S1 right panel).  
In summary, Raman analyses indicated that the digestive process does not induce structural defects 
in FLG, as no significant changes are observed in the I(D)/I(G) and FWHM(D) in the final step 
(intestinal juice). In addition, the changes of the peaks position (D, G and 2D), intensity, and linewidth 
are mainly due to changes in doping, likely because of pH changes. A partial role, however, can be 
also ascribed to the other components of the digestive juices, such as proteins and organic molecules 
that can interact/adsorb to FLG and GOX flakes, forming the so-called protein corona and affecting 
their stability and surface chemistry 25, 64. For the GOX, neither defects are induced nor reduction of 
GOX are observed. Raman observations thus indicate that, when GRMs experience the digestive 
environment, including strong pH variations, degradative enzymes, ions and other organic molecules, 
they do not undergo significant biodegradation processes, unlike other nanomaterials 24, 65, suggesting 
their possible biodurability in the GI tract with unpredictable long-term effects. Moreover, the evident 
doping can change the nature/chemistry of starting materials thus influencing the interaction with 
biological systems. 
 
Assessment of intestinal epithelium integrity upon chronic exposure to digested GRMs 
The intestinal barrier is one of the most important biological barriers within the human body. It 
attends to several functions, such as nutrient uptake, protection against pathogens, and preservation 
of intestinal microbiome 66. The impairment of intestinal homeostasis can lead to uncontrolled 
entrance of pathogens and food antigens as well as in dysregulated nutrient supply, which in turn can 
compromise the health of the entire organism.(REF) Therefore, as a final step of the digestion process, 
we test the biological impact of the digested GRMs on intestinal barrier according to a second SOP 
(https://circabc.europa.eu/sd/a/fe1ea854-be73-4f58-a2ba-
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4bc2ce42ee62/SOP%20for%20the%20evaluation%20of%20NMs%20impact%20on%20Caco2%20
cell%20barrier%20model%2029052015%20V9.pdf). To achieve a reliable in vitro model of 
intestinal barrier, human intestinal epithelial (Caco-2) cells are grown for three weeks on porous 
inserts (Figure 6a). Confocal z-sectioning and TEM images show the formation of a confluent cell 
layer with the typical structures of intestinal epithelium,(REFS) such as cell-cell junctions and 
microvilli (Figure 6b and c). Intestinal barriers are then exposed (up to 9 days) to digested FLG and 
GOX, at the final concentrations of 1 and 5 µg ml
-1, respectively. To choose the dose of GRMs, we 
referred to the human dietary uptake of other nanomaterials.(REF) In fact, for silver nanoparticles, 
concentrations ranging from 1 to 100 µg ml-1 were considered to be a realistic dose range in vitro 65, 
67-68. Additionally, the used FLG and GOX concentrations are selected in order to have the maximum 
possible concentration, allowing good dispersion/stability of the nanomaterials (in particular, the 
concentration of pristine FLG is lower than GOX, due to its worse dispersibility in water, Z-potential 
of 28 mV at pH 7 for FLG and 40 mV for GOX see Figure S1). 
The integrity of the intestinal layer upon chronic incubation with digested GRMs is assessed by 
measuring Trans-Epithelial Electrical Resistance (TEER) and passage to the Bl compartment of LY, 
a marker of paracellular transport (Figure 6d and e). Epithelial layers treated with digested GRMs do 
not show detectable differences in TEER and LY with respect to non-treated controls (Figure 6d and 
e). These results indicated that digested GRMs are well tolerated by the intestinal barrier and does 
not induce its disruption/perturbation upon chronic exposure. Similar results were also reported by 
Bohmert et al. after treatment of Caco-2 cell layers with digested silver nanoparticles 65. In that case, 
no variations in impedance measurements were observed up to 24 h prolonged incubation.  
 
Cellular uptake and intracellular localization of digested GRMs 
Since digested GRMs do not compromise the integrity of the intestinal barrier, their capability to be 
internalized by Caco-2 cell layers was investigated by confocal microscopy after 9 days of chronic 
incubation. As shown in Figure 7a and d, very few spots of both FLG and GOX are observed in the 
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intestinal layers. Confocal z-sectioning of intestinal epithelia stained with phalloidin and Hoechst 
confirmed, from a morphological point of view, that the treatment with digested FLG and GOX do 
not affect cell layer integrity and demonstrated the intracellular localization of GRM spots. Under 
experimental conditions, we observe a limited internalization of GRMs after digestion process, which 
is due to the GRM aggregation when are in contact with the components of digestive juices, as 
suggested by Raman analysis. In fact, we observe large GRM aggregates associated to the intestinal 
barriers and, in some cases, with a preferential accumulation on the cell membrane, in particular along 
cell boundaries in intestinal barriers (Figure S3). The size of these aggregates is variable and around 
some microns (Figure S3). Another important factor that may reduce the cellular uptake of GRMs is 
the differentiation status of Caco-2 cells as enterocytes. In fact, it is reported that the undifferentiated 
Caco-2 cells are more prone than differentiated ones to internalize nanomaterials, such as GOX, 
quantum dots, TiO2 and SiO2 nanoparticles 
21, 69-71. In particular, Kucki et al. recently demonstrated 
that the very dense brush border (made of microvilli) of differentiated intestinal epithelium led to low 
adhesion of GOX sheets and steric hindrance for material uptake 
21. However, a clear understanding 
of GRM internalization into the cells has not yet been achieved, due to the poor internalization and 
the difficulty to have comparable in vitro models 21, 72-75. In TEM images is further confirmed the 
internalization in Caco-2 cell barriers and suggests a vesicular confinement of internalize digested 
FLG (Figure 7 b and c) and GOX (Figure 7 e and f). In general, most nanomaterials use endocytosis 
mechanisms to penetrate the cell membrane and, consequently, they preferentially accumulate into 
endo-lysosomes 23, 39, 69, 76. Therefore, to elucidate the mechanisms of cellular uptake of digested FLG 
and GOX, the lysosomal localization of internalized GRMs within the intestinal barriers is analysed. 
Immunofluorescence results indicate the co-localization of digested GRMs with the lysosomal 
marker LAMP1, thus suggesting that endocytosis contribute to the internalization of FLG and GOX 
flakes (Figure S4).  
Because of the degradative environment of the lysosomal compartment where digested FLG and 
GOX are localized after cellular uptake, additional studies to assess biocompatibility of GRMs on 
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undifferentiated/proliferating Caco-2 cells were carried out. Although only differentiated Caco-2 
cells represent the epithelial cell layer of the small intestines, immature intestinal cells are also present 
in the small intestines, due to cell renewal, and they are proved to be more sensitive to external 
disturbances, e.g., when exposed to silver nanoparticles after in vitro digestion 65. Therefore, viability 
and cell membrane integrity of undifferentiated Caco-2 cells is investigated by 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and 
lactate dehydrogenase (LDH) assays, respectively. To this aim, undifferentiated Caco-2 cells are 
exposed to digested FLG and GOX for 2 hours every day, up to 4 days. Confocal microscopy images 
demonstrate the internalization of digested GRMs in Caco-2 cells (Figure S5a). As expected, the 
uptake of digested GRMs by undifferentiated Caco-2 cells was significantly higher than intestinal 
barriers, because, contrary to the latter, undifferentiated Caco-2 cells lacked the typical structures, 
such as tight junctions and microvilli, which hinder nanomaterial internalization 21, 69-70. Despite such 
higher uptake, both cell viability and cell membrane integrity are not affected by the treatment (Figure 
S5 b and c). Moreover, treatments with non-digested GRMs, used as controls, further indicated 
neither significant decrease in cell viability, nor damage of cell membrane (Figure S5 b and c), in line 
with previously reported data on the same cell type 18-19. Therefore, lack of cytotoxicity in these cells 
after exposure to digested GRMs may likely suggest no toxicity on intestinal barrier. 
 
Inflammatory response of intestinal epithelium to digested GRMs 
In vivo studies on laboratory animals provided some indications that inflammation may be 
involved in the toxicity of GRMs upon inhalation, and that the extent of inflammatory response could 
depend on the physical-chemical characteristics (i.e. lateral size, oxidation) of GRMs 13-14. Therefore, 
the release of inflammatory cytokines in the apical and basolateral media is measured to evaluate the 
possible triggering of inflammation by the intestinal layers upon chronic exposure to the digested 
GRMs. Caco-2 cell layers usually show a significant increase of IL-8 and MCP-1 levels when 
stimulated with inflammatory agents 77-79. In our experiments, the levels of IL-8 and MCP-1 are 
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comparable to untreated cell layers used as negative control (Figure 8). On the contrary, positive 
stimulation with LPS increase the release of the two cytokines (Figure 8). Hence, at variance with 
other nanomaterials 80, digested GRMs do not induce any significant pro-inflammatory effect on the 
intestinal epithelium in vitro. A possible explanation for this effect could be related to the larger 
dimensions of GRMs after digestion, due to aggregation. In particular, GRM aggregates could have 
different transport rates and be retained outside the cell layer, unlike smaller nanomaterials or ions 
that may cross the intestinal layer and reach the cells more easily, inducing stronger inflammatory 
effects. This is consistent with previous findings using Ag nanoparticles, where only smaller 20 nm 
particles up-regulated the IL-8 expression in Caco-2 cell layers, while bigger 100 nm Ag 
nanoparticles did not 77-78. Thus, the immobilization of the large GRM aggregates, due to the size-
exclusion by the intestinal barrier, could result in a reduced cellular uptake and low cytokine release.  
 
Conclusions 
In this work, we investigated the biotransformation and biological impact of few layers graphene and 
graphene oxide flakes upon ingestion, by using the NANoREG standard methods simulating in vitro 
digestion. Our results highlighted the influence of digestive juices in modulating few layers graphene 
and graphene oxide physical-chemical properties. In particular, the interaction of both materials with 
ions and other molecular components present in digestive juices resulted in evident doping effects 
and no structural changes. This interaction influenced the aggregation state of few layers graphene 
and graphene oxidewith important consequences in bioaccessibility of these materials to the intestinal 
layer. In fact, digested GRMs were well tolerated by the intestinal barrier up to 9 days of exposure, 
not inducing detectable damage, even though large GRM aggregates were associated to its apical 
side. The immobilization of the GRM aggregates, due to the size-exclusion by the typical brush border 
of the intestinal barrier, resulted in: i) reduced cellular internalization, ii) no short-term cytotoxicity 
and iii) low cytokine release. However, because of the observed GRMs biodurability, regardless of 
the complex and harsh environments they experienced during the digestion simulation and their 
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partial cellular uptake, additional investigations on their long-term fate are necessary in future studies 
to further assess their biocompatibility profile.  
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Figure 1. Schematic representation of the in vitro digestion assay of GRMs. Along the passage 
through the different digestive compartments (mouth, stomach and small intestine), chemical-
physical changes of FLG and GOX were monitored by Raman spectroscopy. Synthetic digestive 
juices are used and all relevant parameters during digestion process such as temperature, pH changes, 
transit times, relevant enzymes, and protein compositions are considered. 
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Figure 2. Graphene and graphene oxide characterization. Representative transmission electron 
microscopy images of FLG (a) and GOX (b) nanosheets. Lateral dimension distribution of FLG (c) 
and GOX (d) flakes measured by TEM image analysis. Thermogravimetric analysis of FLG (e) and 
GOX (f) Zeta potential of FLG (g) and GOX (H) measured at 25 °C and dispersed in MilliQ water. 
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Figure 3. Representative Raman spectra (@514 nm) of GRMs and digestive juices. Few-layers 
graphene and graphene oxide spectra are reported in blue and purple, respectively. Red, green and 
yellow represent Raman spectra of the digestive juices: saliva, stomach and intestine. 
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Figure 4. Raman statistical analysis of FLG dispersions in saliva, stomach and intestine juices. 
a) Pos(G), b) FWHM(G), c) Normalized intensity I(D)/I(G) and d) FWHM(D) of FLG. 
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Figure 5. Raman statistical analysis of GOX dispersions in saliva, stomach and intestine juices. 
a) Pos(G), b) FWHM(G), c) Normalized intensity I(D)/I(G) and d) FWHM(D) of GOX flakes. 
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Figure 6. Characterization of the intestinal epithelium formation and integrity after chronic 
exposure to digested FLG and GOX. a) Schematic representation of the intestinal epithelium in vitro 
model; b) TEM micrograph of 21 day-grown intestinal layer showing microvilli and cell-cell junction 
formation; c) Representative z-sectioning confocal microscopy image of a confluent intestinal layer 
after 21 days of growth on permeable inserts. Cells are stained with phalloidin (red) and Hoechst 
33342 (blue) to highlight actin microfilaments and nuclei. Lateral boxes represent z-stack projections 
along x-z and y-z axis; d) TEER measurements of non-treated control intestinal epithelial layers (Ctrl) 
and intestinal epithelial layers after 1, 5 and 9 days of chronic exposure to digested FLG and GOX; 
e) percentage of transported LY across the intestinal epithelium after 1, 5 and 9 days of chronic 
exposure to digested FLG and GOX compared with non-treated control intestinal layers (Ctrl). Data 
represent the average of three different experiments performed in triplicate and the error bars 
represent the standard deviation. 
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Figure 7. Uptake and intracellular localization of digested FLG and GOX nanosheets in Caco-2 
intestinal epithelium. Representative z-sectioning confocal microscopy images of confluent 
intestinal layers after 9-day chronic incubation with digested FLG (a) and GOX (d). Cells are stained 
with phalloidin (red) and Hoechst 33342 (blue) to highlight actin microfilaments and nuclei, 
respectively, and FLG and GOX are acquired by reflected light (cyan). Lateral boxes represent z-stack 
projections along x-z and y-z axis. TEM micrographs of digested FLG (b and c) and GOX (e and f) 
nanoflakes internalized in Caco-2 cell barriers after 9-day chronic incubation. c) and f) are the zoomed 
areas highlighted by the yellow dashed squares in b) and e), respectively. Yellow arrows indicate 
GRM flakes.   
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Figure 8. Inflammatory response of Caco-2 intestinal layer upon chronic exposure to digested 
FLG and GOX flakes. Release of IL-8 in apical and basolateral compartments and MCP-1 in 
basolateral compartment.  
 
 
